Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
267 people get CRL articles and Market Currents by email alert.
Get email alerts on CRL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 6, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Jan 22, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Jan 7, 2013)
-
Strengthening Moats Mean Improving Returns For CRO InvestorsMorningstar • Mon, Dec 31, 2012
-
5 Stocks With Unusual VolumeMike King • Thu, Dec 13, 2012
-
Charles River Laboratories' CEO Discusses 2013 Guidance (Transcript)Wed, Dec 12, 2012
-
Business Wire (Dec 12, 2012)
-
3 Repurchase Plans For Fiscal UncertaintyPrescient Investment Analysis • Mon, Dec 10, 2012
To learn more about Seeking Alpha Pro, click here.
-
Buy One, Get One Free At Charles River LaboratoriesMorningstar • Sun, May 13, 2012
-
Charles River Placates Investors With More CutbacksThe Burrill Report • Thu, Dec 16, 2010
-
Charles River Falls Short as Higher Costs Take Their TollZacks Investment Research • Mon, Apr 26, 2010
-
Charles River Labs Looking for Second China FacilityChinaBio Today • Thu, May 7, 2009
-
Charles River Blames Slowdown on Biopharmas' Need to Conserve CashChinaBio Today • Sun, Nov 9, 2008
-
Charles River and Shanghai BioExplorer Open CRO FacilityChinaBio Today • Thu, Oct 16, 2008
-
Charles River Labs Attributes Success to "Virtualization" of PharmaChinaBio Today • Wed, Feb 13, 2008
-
Can Charles River Laboratories Make the Most of the Rat Race?James Hale • Wed, Feb 7, 2007
-
Charles River Laboratories: Driving The Rat RaceJames Hale • Wed, Nov 1, 2006
-
Strengthening Moats Mean Improving Returns For CRO InvestorsMorningstar • Mon, Dec 31, 2012
-
5 Stocks With Unusual VolumeMike King • Thu, Dec 13, 2012
-
3 Repurchase Plans For Fiscal UncertaintyPrescient Investment Analysis • Mon, Dec 10, 2012
-
16 Rallying Healthcare Stocks Being Sold By Hedge FundsKapitall • Tue, Feb 21, 2012
-
Contract Research Organizations Still On Sale As Industry ReboundsMorningstar • Thu, Jan 12, 2012
-
Hedge Funds Are Selling These 6 Biotech StocksKapitall • Wed, Jan 11, 2012
-
Top 10 Biotech Stocks Loved By Hedge FundsInsider Monkey • Thu, Dec 29, 2011
-
Charles River Laboratories' CEO Discusses 2013 Guidance (Transcript)Wed, Dec 12, 2012
-
Charles River Laboratories 2008 Guidance Call TranscriptThu, Dec 13, 2007
-
Charles River Laboratories Q3 2007 Earnings Call TranscriptTue, Nov 6, 2007
-
Business Wire (May 6, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 8, 2013)
-
Business Wire (Mar 1, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Jan 22, 2013)
-
at CNBC.com (Jan 9, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Jan 7, 2013)
-
at MarketWatch.com (Dec 12, 2012)
-
Business Wire (Dec 12, 2012)
-
Business Wire (Nov 29, 2012)
-
Business Wire (Oct 30, 2012)
-
Business Wire (Oct 30, 2012)
-
Business Wire (Oct 17, 2012)
-
Business Wire (Oct 1, 2012)
-
Business Wire (Sep 10, 2012)
-
Business Wire (Aug 29, 2012)
-
at MarketWatch.com (Aug 8, 2012)
-
Business Wire (Aug 7, 2012)
CRL vs. ETF Alternatives
Company Description
Charles River has been operating since 1947 and during that time, we have undergone several changes to our business structure. Charles River Laboratories International, Inc. was incorporated in 1994. In 2000, we completed the initial public offering of Charles River Laboratories International,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 1, 4:56 PM Charles River (CRL): Q1 EPS of $0.69 misses by $0.02. Revenue of $291.2M misses by $0.34M. (PR) Comment! [Earnings, Breaking News]
- Wednesday, February 13, 4:42 PM Charles River (CRL): Q4 EPS of $0.64 beats by $0.04. Revenue of $280.1M misses by $0.71M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, December 13, 2012, 1:25 PM Charles River Labs (CRL +3.2%) moves higher on a couple of upgrades earlier today. JPMorgan raises its rating on the shares to Overweight, saying the risk-reward is looking good going into 2013. The firm notes that longer term questions still remain, but given the improving fundamentals, ongoing cost discipline and a 10% free cash flow yield, the stock looks attractive at current levels. Separately, Wells Fargo also upped the shares to Outperform on valuation, saying that that guidance looks conservative with the midpoint only 5% below consensus. Comment! [Healthcare, On the Move]
-
Wednesday, December 12, 2012, 12:45 PM
Midday top 10 gainers: YMI +77%. DSTI +73%. TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%.
Midday top 10 Losers: RSOL -14%. CENT -13%. ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. CRL -8%. AXK -8%. LTBR -8%. Comment! [On the Move] - Wednesday, December 12, 2012, 9:29 AM Charles River Labs (CRL) -5.1% premarket after providing 2013 earnings guidance below expectations, at $2.80-$2.90 per share vs. $3.01 consensus estimate. The drug research services provider also expects 2012 EPS to come in between the low end and the midpoint of its previously estimated range of $2.68-$2.73. Comment! [Healthcare, On the Move]
- Tuesday, October 30, 2012, 4:44 PM Charles River Laboratories International (CRL): Q3 EPS of $0.65 beats by $0.03. Revenue of $278.7M (flat% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Wednesday, October 17, 2012, 8:28 AM AstraZenica (AZN) chooses Charles River (CRL) as its partner for in vivo biology, which will allow AZN to create a "flexible research platform." The deal is for three years and is expected to contribute approximately 1% to Charles Rivers' total net sales in 2013. (PR) Comment! [Healthcare]
- Saturday, October 13, 2012, 10:00 AM Five years after record fundraising for P-E firms, the shops still sit on much of that cash and are coming up against the time when they must "use-it-or-lose-it." As most would rather use it, Barron's screens for attractive targets - market cap of $1B-$10B, an Enterprise Value/EBITDA ratio below 10, and annual cash flow of at least 5% of stock market value. The winners: Guess (GES), Terex (TEX), Charles River Labs (CRL), and Big Lots (BIG). 1 Comment [Quick Ideas, M&A]
- Wednesday, August 29, 2012, 2:25 PM Charles River Laboratories (CRL +0.4%) acquires Accugenix , a global provider of cGMP-compliant contract microbial identification testing, for around $17M in cash. The acquisition is intended to strengthen CRL's Endotoxin and Microbial Detection1 portfolio by providing clients with state-of-the-art microbial detection services for manufacturing in the biopharmaceutical, medical device, nutraceutical and consumer care industries. Comment! [Healthcare, M&A]
- Tuesday, August 7, 2012, 4:46 PM Charles River Laboratories (CRL): Q2 EPS of $0.75 beats by $0.09. Revenue of $284.7M (-1.2% Y/Y) misses by $2M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, May 2, 2012, 5:06 PM Charles River Laboratories (CRL): Q1 EPS of $0.70 beats by $0.05. Revenue of $286M (flat Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Monday, February 13, 2012, 7:04 PM More on Charles River Labratories (CRL): Q4 beats both revenue and per share estimates on better than expected product demand and the absence of prior-year write-downs. The company also reafirms FY12 guidance. Comment! [Healthcare, Earnings]
- Monday, February 13, 2012, 4:52 PM Charles River Laboratories (CRL): Q4 EPS of $0.69 beats by $0.14. Revenue of $291M (+3.3% Y/Y) beats by $9M. Shares +2.6% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Wednesday, January 11, 2012, 4:30 PM With speculation high that Charles River Labs (CRL) is in play, William Blair estimates a deal could be worth at least $40 and maybe more than $60, with the most likely price in the mid-$40s (today's close was $31.34). Shares fell 3.5% today, but remain up 13% on the week. Comment! [M&A, Healthcare]
- Tuesday, January 10, 2012, 11:25 AM Speculation that Charles River Laboratories (CRL) is in play intensifies as management stays mum, shares are now up 22.8% without breaking stride. Comment! [On the Move]
- Tuesday, January 10, 2012, 8:23 AM Charles River Labs (CRL) is pursuing a sale of the company that could fetch as much as $40/share, and it's "just a matter of time" before a deal is completed, the Deal Reporter says. R.W. Baird expects shares to trade higher on the speculation unless management denies the story. CRL +2.1% premarket. Comment! [Healthcare, M&A, On the Move]